Introduction
At the somatic level only a few genes are found mutated in breast tumours, although genomic instability is detected at a high frequency. Losses of several chromosome regions are recurrently reported, as are amplifications, though to a lesser degree. The amplified regions include well characterized oncogenes, like MYC, ERBB2 and CCND1, but amplifications are only found in a minority of tumours (15-30% for each gene) (reviewed by larly, mutations in well defined tumour suppressor genes (TSGs) are relatively rare in breast cancer; TP53 is mutated in about 20-30% of breast tumours and to a much lesser degree CDH1, which is found mutated in 56% of lobular breast cancer. 2 Recently, several publications have demonstrated abnormalities at the FHIT (fragile histidine triad) locus in considerably high frequency in either primary breast tumours or cell lines. These include loss of heterozygosity (LOH), as demonstrated using intragenic microsatellite markers, homozygous deletions, hypermethylation of the promoter region, abnormally sized transcripts, and reduced RNA and protein expression. However, no mutations have yet been reported in the FHIT gene in breast cancer cells.
The FHIT gene and Fhit protein
The FHIT gene is located at the FRA3B site of chromosome 3p14.2, and is so far the only example of a gene located in a constitutive fragile region. 3 The FHIT gene is composed of 10 exons which span a 1.8 Mb genome region of which only exons 5-9 are protein coding ( Figure 1 ). Despite spanning a large genomic region, the FHIT gene encodes a small mRNA of 1.1 kb and a small protein of 16.8 kDa. Alternative splicing of the FHIT pre-mRNA has been suggested, but definite characterization of different splicing products in normal cells has not been worked out and so far no alternative proteins have been described. The yeast homologue of FHIT is the enzyme diadenosine tetraphosphate (Ap(4)A) hydrolase. 4 In higher eukaryotes Fhit may reduce the intracellular level of diadenosine triphosphate, by binding to it and inducing its hydrolysis. A putative role for diadenosine triphosphate in the growth control of the cell has been suggested. 4, 5 Murphy et al. 5 showed that Fhit metabolizes Ap3A and Ap3N but not Ap4A or Ap4N in vivo. It is well known that Ap3A/Ap4A ratio is essential for functional activity of ApnA. In addition to Fhit the Ap4A/Ap3A ratio is controlled by other proteins. TrpRS specifically stimulates the production of Ap3A while Fhit degrades it and the Ap4A/Ap3A ratio can therefore be modulated by changing the activity/ratio of TrpRS/Fhit proteins. 7 The function of ApnA has been associated with several cell growth control functions, such as the stimulation of DNA synthesis, mitogen activity, gene transcription and the regulation of membrane bound ion channels. 6 Fhit is a homodimer as shown conclusively by crystallographic analysis in two laboratories. 8, 9 Interestingly, both in Drosophila and C. elegans the FHIT homologues are part of a larger fusion protein with nitrilase, i.e. NitFhit protein. 10 Expression studies in humans and mice have shown that this protein has nearly identical expression patterns to Fhit, which, together with the presence of the NitFhit fusion protein in the worm and the fly, suggests their involvement in the same biochemical pathway. Fhit protein expression is detected in epithelial cells in most human and mouse tissues. 3, 11 The Fhit protein is mainly localized in the cytoplasm and has been found in a complex with tubulin and a ubiquitin conjugating enzyme. 12, 13 
FHIT alterations in breast cancer
In tumours associated with environmental carcinogens, alterations in the FHIT gene occur early in cancer development, but in other cancers this is thought to be a late event and possibly associated with cancer progression (reviewed by Croce et al., 1999) . 14 Cancer specific translocations have been mapped within the FHIT gene in renal cell carcinoma and a papilloma virus insertion site in cervical carcinoma. [15] [16] [17] The breakpoint at 3p14.2, involved in the t(3;8) chromosome translocation of hereditary renal cell carcinoma, interrupts the third intron of the FHIT gene, inactivating one of the two FHIT alleles. 3 Frequent allelic losses at this region in various malignancies, including breast carcinomas, imply that FHIT may represent a TSG (Table 1) . LOH at the FHIT locus is detected in a subset of breast tumours, with the highest frequency in familial breast cancer lacking functional BRCA2 in the tumours, presumably due to lack of DNA repair. 19, 21, 23, 24 Cell lines from several tumour types, including breast cancer, carry homozygous deletions at the FHIT locus (Table 1) . 11, 16, 18, 20 In addition to LOH, homozygous deletions at chromosome 3p14 have been found in sporadic breast cancer and benign proliferative breast disease. [27] [28] [29] No expression of Fhit was observed, probably as a result of the homozygous deletion. 29 Additional reports suggest reduced mRNA expression in a subset of breast cancer, and FHIT gene loss has been shown to be associated with reduced Fhit protein expression in both ductal and lobular breast cancer (Table 2) . 19, 22, 25 Abnormal sizes of mRNA have been reported to be tumour specific in several cancer types, including breast cancer (Table 2) . 19, 20, 30 The role of low abundance aberrant FHIT transcripts is uncertain, particularly when wild type transcripts are co-expressed in the tumour cells. Still, a dominant negative mechanism is possible. Hypermethylation in the FHIT promoter region has been detected in 12/39 (31%) of primary breast carcinomas and in 19/22 (86%) of breast cancer cell lines. 32 This methylation is allele specific and results in reduced expression of the gene, as detected by immunohistochemistry. Alterations at the FHIT locus, or reduced expression of Fhit, has been associated with breast tumour progression and survival of breast cancer patients. 26, 31, 33 In general, the findings listed are in line with the tumour suppressor function of the Fhit protein. However, it has been argued that the FHIT gene may be altered in cancers simply because it is located at a fragile region and is likely to be susceptible to breakage. In support of this view is the observation that somatic point mutations in FHIT are rarely found in breast or other tumours, and germline mutations do not seem to be significant. 20, 34, 35 As outlined in the next section, the definite proof of a tumor suppressor function of FHIT has been established by various functional analyses. 
Functional aspects of FHIT with respect to tumour growth
A variety of evidence argues for the tumour suppressor role of FHIT in breast cancer and other tumour types. Tumourigenicity can be reduced in lung, cervix and kidney cell lines after reintroduction of the FHIT gene. [36] [37] [38] Of interest is the observation that a mutated form of Fhit, lacking the Ap3A hydrolase activity, also suppresses tumourigenicity, suggesting that the tumour suppressor activity of FHIT is not related to catalysis of nucleotide substrates. 37 Perhaps the binding of Ap3A to Fhit is sufficient to suppress the malignant phenotype. Similarly, with the use of the human/mouse microcell hybrid, it was demonstrated that the introduction of chromosome 3 into a mouse fibrosarcoma line reduces tumourigenicity, whereas elimination of the FHIT locus enhances tumourigenesis. 39 A definite proof of the tumour suppressor function of Fhit was demonstrated with the generation of Fhit knockout mice. 40 Both heterozygous (Fhit+/−) and homozygous (Fhit−/−) Fhit knockout mice spontaneously develop tumours at increased frequency. Although some of the Fhit knockout mice have been reported to develop tumours with a similar spectrum to humans with Muir-Torre syndrome, the full spectrum of tumours that will develop spontaneously in Fhit+/− and Fhit−/− mice has not yet been reported. 40, 41 Both Fhit+/− and Fhit−/− mice are also more susceptible to carcinogen-induced tumours of the oesophagus and forestomach. 40 Treatment of the Fhit knockout mice with adenovirus and AAV based expression of the Fhit reduces the malignant phenotype. 41 Apart from the ability of Fhit to bind and hydrolyse Ap3A, little is known of the biochemical and biological function of the Fhit with respect to its tumour suppressor ability. Overexpression of Fhit in tumour cell lines lacking Fhit expression induces significant growth arrest, caused both by increased apoptosis and G1 cell cycle arrest. 38, 42, 43 The ubiquitin conjugating enzyme, hUBC9, is associated with the C-terminal portion of Fhit, and this interaction is independent of Fhit enzymatic activity. 13 Since the yeast UBC9 is involved in the degradation of S-and M-phase cyclins, Fhit may be involved in cell cycle control through its interaction with hUBC9. 13 Similarly, it has been shown that intracellular concentration of ApnA can affect apoptotic pathways. 44 
FHIT loss: a marker of genetic instability or loss of a tumour suppression?
The FHIT gene is located at the most active common fragile site in the human genome, the aphidicolin sensitive site FRA3B. 3 The fragility of this site can presumably be explained by late replication, which can be further delayed by inhibiting the DNA polymerase activity by aphidicolin. 45 The behaviour of genomic fragile sites is not well documented in relation to tumour initiation and progression, but studies on the FHIT locus give an excellent opportunity to characterize such a site in cancer development. Tumour cells frequently exhibit genomic instability but little is known about the status of common fragile sites in relation to this instability. Genetic instability in tumours can be divided into microsatellite instability (MIN) and chromosome instability (CIN) (reviewed by Cahill et al., 1999) . 46 The MIN phenotype is well characterized and is observed in almost all cases of HNPCC (hereditary non-polyposis colorectal carcinoma) and in a proportion of sporadic tumours of the colon, stomach, endometrium, lung, and some other tumour types. Intragenic microsatellite markers within introns of the FHIT gene show instability in MIN tumours to a similar level to microsatellites outside the gene. The relevance of these mutations to tumour development is, however, not clear. The MIN phenotype is rare in breast cancer. 47 The CIN phenotype is not as well defined as the MIN phenotype, but a relatively high proportion (60-70%) of breast cancers show aneuploidy, that may reflect a CIN phenotype. [48] [49] [50] LOH of FHIT intragenic markers have been found slightly elevated in aneuploid compared to diploid breast tumours (37% versus 28%), but this does not reach statistical significance. 26 In the same study it was shown that LOH at the FHIT locus is associated with LOH at 12 different chromosome arms. 26 One type of genomic instability that can be classified as CIN is detected in breast tumours from carriers of BRCA1 and BRCA2 germline mutations. 24, 51 Lack of proper DNA repair in these tumours is presumably the reason for this instability. These tumours show elevation of gains and losses of certain chromosomes that are characteristic, depending on whether the BRCA1 or BRCA2 function is lost. In BRCA2 mutated tumours, a frequent FHIT LOH is observed and the Fhit protein expression is reduced. 24, 25 As concluded from the analysis of LOH at several chromosomal regions, as distinct from 3p, in BRCA2 mutated tumours, the presence of a common fragile site alone cannot explain increased LOH frequency in these tumours, and the growth advantage of the breast tumour cells may be of importance for the clonal selection of the chromosome losses. 24, 52 In general, the FHIT gene seems to be aberrant in tumours with at least certain types of genomic instability, and this suggests that it can serve as a marker for genomic instability. This unstable nature of FHIT in tumours does not, however, rule out its putative role as a tumour suppressor.
Conclusion
The protective effects of Fhit vis-à-vis tumorigenicity implies that Fhit is directly involved in the control of cell growth and/or proliferation. A definite mechanism to explain the anti-tumour role of Fhit has so far not been worked out. The acceptance of FHIT as a tumour suppressor has not been universal, since some reports suggest that the fragility of the locus alone could account for clonal or oligoclonal genetic alterations of FHIT in cancer. Still, compelling evidence on the effects of FHIT on cellular behaviour is in line with its role as a tumour suppressor. These data, together with frequent alterations of the FHIT locus in breast cancer, suggest its role in the pathogenesis of breast tumours.
